Recombinant hemagglutinin influenza vaccine

Recombinant hemagglutinin influenza vaccine has been studied in 1 paper since 2016: 1 trial in people. The newest paper, Jan 19, 2016: “Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans”.

Intervention

1 paper studies it1 findingUpdated

See all 1 papers on recombinant hemagglutinin influenza vaccine

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Adults showed the highest induction of stalk-specific antibodies, but the elderly had the highest absolute antibody titers against the stalk”
Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in HumansmBio2016doi:10.1128/mbio.01996-15
Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funders: National Institute of Allergy and Infectious Diseases and 2 more
  • 1 of 1 finding with company ties
  • Human trial1

Studies in people

1 study gave recombinant hemagglutinin influenza vaccine to people and measured what changed.

What changedDesignPeopleSource

up: Increases hemagglutinin stalk-reactive antibodies

Treated cohortchildren (6 to 59 months), adults (18 to 49 years), elderly (≥65 years)Midlife adults; Older adults; Across the life coursemBio, Jan 19, 2016

What did studies of recombinant hemagglutinin influenza vaccine find?

1

Studies of recombinant hemagglutinin influenza vaccine measured one outcome, hemagglutinin stalk-reactive antibodies.

Hemagglutinin stalk-reactive antibodies

upin humans1

1 study
  1. Recombinant hemagglutinin influenza vaccine increases hemagglutinin stalk-reactive antibodies in humans.

    “Adults showed the highest induction of stalk-specific antibodies, but the elderly had the highest absolute antibody titers against the stalk”

    Human trialserum

    Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans

    mBio

More on Hemagglutinin stalk-reactive antibodies

Latest